Neflamapimod, an experimental oral therapy from Cervomed, has been selected for inclusion in the U.K.-funded EXPERTS-ALS platform study.

Using human induced pluripotent stem cells, researchers have built a miniature 3D liver model that replicates the critical interaction between hepatocytes and stellate cells. As chronic liver disease ...